The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
== Commercial sources == The world's supply of pure (mostly anhydrous) caffeine for adding to drinks, pharmaceuticals, and other products comes from two sources: industrial synthesis and decaffeination of natural sources. Despite the different production methods, the final products are chemically identical, as are their effects on the body. Research on synthetic caffeine supports that it has the same stimulating effects on the body as natural caffeine. Although many claim that natural caffeine is absorbed slower and therefore leads to a gentler caffeine crash, there is little scientific evidence supporting the notion. Nevertheless, a demand for natural caffeine to satisfy consumer perception has grown so large that the decaffeinated product may be now considered a byproduct for the production of caffeine. The global market exchanged 128,127 tons of anhydrous caffeine in 2022. Most of the world's synthetic caffeine is produced by Chinese pharmaceutical companies, but an exact breakdown of supply between synthetic and natural does not seem to be available. It is possible to distinguish between natural and synthetic caffeine using carbon-13-to-carbon-12 isotope ratios, as most of the carbon from synthetic caffeine comes from petroleum sources with a more "ancient" carbon isotope signature.
A 2007 study found that carriers of at least one C allele (variant CC or CT) are 7.72 times more likely than non-carriers to achieve remission after 4 weeks of treatment with amitriptyline, citalopram, paroxetine or venlafaxine (all P-gp substrates). The study included patients with mood disorders other than major depression, such as bipolar II; the ratio is 9.4 if these other disorders are excluded. At the 6-week mark, 75% of C-carriers had remitted, compared to only 38% of non-carriers.
Copper histidinate, sold under the brand name Zycubo, is a medication used for the treatment of Menkes disease. Copper histidinate is a copper replacement therapy given by subcutaneous injection. The most common side effects include infections, respiratory problems, seizures, vomiting, fever, anemia and injection site reactions. Copper histidinate was approved for medical use in the United States in January 2026.
It has been suspected that the Bolivian police themselves have a responsibility in promoting anti-Peruvian xenophobia, trying to blame Peruvians for the increase in crime (in instead of Bolivia's internal problems), as well as not efficiently preserving the human rights of Peruvian migrants in the face of outrages. For example, Colonel Javier Gómez Bustillos of the Bolivian Police (markedly anti-Peruvian) would have carried out attacks to Peruvian citizens in May 2001, and despite this, he continued to receive the protection of his government and his institution, who would have promoted him to the best positions in his institution instead of making him answer to the law. The Bolivian press and The media would have helped the development of this current of anti-Peruvian opinion, getting it to position itself in the Bolivian masses, by giving great emphasis in its programs to criminal acts carried out by Peruvian migrants, including the most serious crimes such as drug trafficking and those related to subversion. The death of a Peruvian soldier, the sailor Juan Vega Llana, also contributed to the latter, due to the fact that he was assassinated, in a central street of La Paz, by Peruvian people (classified as subversive) who were members of the terrorist group Sendero Luminoso, who They sought revenge for the Massacre in the prisons of Peru.
Sources: en.wikipedia.org
== Achievements == In what was described by The Guardian UK as "The Toughest Job in Nigerian Healthcare," Muhammad served as Executive Director/CEO of the National Primary Health Care Development Agency (NPHCDA) from November 2011, he played a key role in Nigeria's successful eradication of polio. He established the National Polio Emergency Operations Centre in October 2012 and introduced community engagement innovations such as health camps, polio survivor groups, religious leaders, volunteer mobilizers, and child-friendly incentives. These efforts reduced wild poliovirus cases from 122 in 2012 to 53 in 2013 and six in 2014 (an 89% decline), with no new cases for over a year by mid-2015. Nigeria was removed from the polio-endemic list in September 2015, earning global praise from the WHO, Bill Gates, and partners as a model for Africa. The Emergency Operations Centre model was later adapted for epidemic responses across Africa, including during the COVID-19 pandemic for coordination, surveillance, and community engagement in Nigeria and beyond. He also strengthened routine immunization by deploying over 6,000 frontline workers, improving cold chain infrastructure, and rolling out the pentavalent vaccine nationwide to boost uptake. Additionally, he launched the "Primary Healthcare Under One Roof" initiative to consolidate services under state agencies, improving coordination and efficiency in Nigeria's federal system.
The human body contains, on average, 50–60% water, depending on age, gender and body size, although individuals may have anywhere between 45% and 75%. The U.S. National Academies of Sciences, Engineering, and Medicine recommends a daily intake of 3.7 liters (0.98 U.S. gallons) of water for adult men and 2.7 L (0.71 U.S. gal) for women. The precise amount depends on the level of activity, temperature, humidity, and other factors. Most of this is ingested through foods or beverages other than drinking straight water. Medical literature favors a lower consumption, typically 1 liter of water for an average male, excluding extra requirements due to fluid loss from exercise or warm weather. Healthy kidneys can excrete 0.8 to 1 liter of water per hour, but stress such as exercise can reduce this amount. People can drink far more water than necessary while exercising, putting them at risk of water intoxication (hyperhydration), which can be fatal. The popular claim that "a person should consume eight glasses of water per day" seems to have no real basis in science. Studies have shown that extra water intake, especially up to 500 millilitres (18 imp fl oz; 17 US fl oz) at mealtime, was associated with weight loss. Adequate fluid intake is helpful in preventing constipation.
A vitamer () is any form in which some vitamin occurs. Each vitamer of a particular vitamin is a compound that performs the functions of that vitamin and prevents the symptoms of deficiency of the vitamin. Early research identified vitamins by their ability to cure vitamin-specific deficiency diseases. For example, vitamin B1 was first identified as a substance that prevented and treated beriberi. Subsequent nutrition research has revealed that all vitamers exhibit biological activity against their specific vitamin deficiency, although different vitamers exhibit different potencies against those diseases. A set of vitamers with related biological activity are grouped together by a general name, or generic descriptor, that refers to similar compounds with the same vitamin function. For example, vitamin A is the generic descriptor for the class of vitamin A vitamers which includes retinol, retinal, retinoic acid, and provitamin carotenoids such as beta-carotene, among others.
wild type (WT) Denoted in shorthand with a + superscript. The phenotype of the typical form of a species as it occurs in nature; a product of the standard "normal" allele at a given locus, as opposed to that produced by a non-standard mutant allele.
The current in an LED or other diodes rises exponentially with the applied voltage (see Shockley diode equation), so a small change in voltage can cause a large change in current. Current through the LED must be regulated by an external circuit such as a constant current source to prevent damage. LEDs are sensitive to voltage. They must be supplied with a voltage above their threshold voltage and a current below their rating. Current and lifetime change greatly with a small change in applied voltage. They thus require a current-regulated supply (usually just a series resistor for indicator LEDs). Efficiency droop: The efficiency of LEDs decreases as the electric current increases. Heating also increases with higher currents, which compromises LED lifetime. These effects put practical limits on the current through an LED in high power applications.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.